Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14507959 | 0.87 | RAB9A (0.38) | SMN1; SMN2RAB9ANPSR1HPGDALDH1A1 | |
| SCHEMBL8283341 | 0.87 | ALDH1A1 (0.39) | SMN1; SMN2RAB9ANPSR1HPGDALDH1A1 | |
| SCHEMBL8284114 | 0.86 | HSD17B10 (0.33) | SMN1; SMN2RAB9ANPSR1HPGDLMNA | |
| SCHEMBL8284881 | 0.85 | LMNA (0.34) | SMN1; SMN2RAB9ANPSR1HPGDLMNA | |
| SCHEMBL8284130 | 0.85 | CTSS (0.43) | — | |
| SCHEMBL14507994 | 0.85 | SMN1; SMN2 (0.34) | SMN1; SMN2RAB9AHPGDLMNAALDH1A1 | |
| SCHEMBL8284128 | 0.84 | LMNA (0.33) | SMN1; SMN2RAB9ANPSR1HPGDLMNA | |
| SCHEMBL8283325 | 0.84 | SMN1; SMN2 (0.34) | SMN1; SMN2RAB9ANPSR1HPGDLMNA | |
| SCHEMBL8284006 | 0.83 | ALDH1A1 (0.35) | SMN1; SMN2RAB9ANPSR1HPGDLMNA | |
| SCHEMBL8283337 | 0.82 | NPPA (0.34) | SMN1; SMN2RAB9ANPSR1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2005063742-A2 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105892-A1 | Amidino compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | SMN1; SMN2 4478/4885RAB9A 966/4885NPSR1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.